Alkem Laboratories Ltd
NSE:ALKEM

Watchlist Manager
Alkem Laboratories Ltd Logo
Alkem Laboratories Ltd
NSE:ALKEM
Watchlist
Price: 5 406.3 INR -1.38% Market Closed
Market Cap: 646.4B INR
Have any thoughts about
Alkem Laboratories Ltd?
Write Note

Relative Value

The Relative Value of one ALKEM stock under the Base Case scenario is 5 494.23 INR. Compared to the current market price of 5 406.3 INR, Alkem Laboratories Ltd is Undervalued by 2%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALKEM Relative Value
Base Case
5 494.23 INR
Undervaluation 2%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
4
vs Industry
26
Median 3Y
3.9
Median 5Y
3.8
Industry
2.5
Forward
4.6
vs History
31
vs Industry
12
Median 3Y
33.4
Median 5Y
27.6
Industry
21.8
Forward
28.4
vs History
28
vs Industry
14
Median 3Y
31.7
Median 5Y
31
Industry
16.1
vs History
23
vs Industry
10
Median 3Y
54.3
Median 5Y
40.6
Industry
23.8
vs History
4
vs Industry
12
Median 3Y
4.8
Median 5Y
4.8
Industry
2.1
vs History
4
vs Industry
26
Median 3Y
3.8
Median 5Y
3.7
Industry
2.7
Forward
4.4
vs History
4
vs Industry
28
Median 3Y
6.2
Median 5Y
6.1
Industry
5.2
vs History
4
vs Industry
13
Median 3Y
23
Median 5Y
20.7
Industry
13.5
Forward
23.1
vs History
7
vs Industry
14
Median 3Y
27.9
Median 5Y
25.3
Industry
16.8
Forward
26.4
vs History
31
vs Industry
15
Median 3Y
30.3
Median 5Y
29.7
Industry
15.2
vs History
49
vs Industry
13
Median 3Y
37.5
Median 5Y
38.4
Industry
19.3
vs History
4
vs Industry
14
Median 3Y
4.3
Median 5Y
4.1
Industry
1.9

Multiples Across Competitors

ALKEM Competitors Multiples
Alkem Laboratories Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Alkem Laboratories Ltd
NSE:ALKEM
646.4B INR 5.1 31.5 25.3 28.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.2B USD 18.5 89.9 48.1 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
350.6B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
252B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.4 10.5 15.9
P/S Multiple
Revenue Growth P/S to Growth
IN
Alkem Laboratories Ltd
NSE:ALKEM
Average P/S: 382 942.4
5.1
31%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
IN
Alkem Laboratories Ltd
NSE:ALKEM
Average P/E: 32.2
31.5
56%
0.6
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.9
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.4
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Alkem Laboratories Ltd
NSE:ALKEM
Average EV/EBITDA: 416.1
25.3
54%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Alkem Laboratories Ltd
NSE:ALKEM
Average EV/EBIT: 1 813
28.8
56%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

See Also

Discover More
Back to Top